The Total number of records shown on this page is 44. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_3163	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell line22Rv1	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit 1 assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3164	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell line22Rv1	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit 1 assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3165	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell line22Rv1	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit 1 assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3166	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell line22Rv1	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit 1 assay	In-vitro virus concentration10 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3167	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineVCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit 1 assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3168	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineVCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit 1 assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3169	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineVCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit 1 assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3170	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineVCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit 1 assay	In-vitro virus concentration10 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3171	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCalcein AM assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3172	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCalcein AM assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3173	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCalcein AM assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3174	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell line40000 cells per well	In-vitro toxicityNA	AssayCalcein AM assay	In-vitro virus concentration10 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3175	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismCAnM.Cg-Foxn1nu/Crl Balb/c nude mice subcutaneous xenograft for LNCaP (5.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 20 days	Mode of deliveryIntraperitoneal	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3176	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismCAnM.Cg-Foxn1nu/Crl Balb/c nude mice subcutaneous xenograft for LNCaP (5.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 20 days	Mode of deliveryIntraperitoneal	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_5126	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5127	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5128	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5129	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result42% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5130	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5131	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5132	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result82% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5133	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result71% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5134	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result44% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5135	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine neuroblastoma cell line	Cell lineNXS2	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5136	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5137	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5138	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result88% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5139	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5140	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5141	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result88% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5142	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5143	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result80% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5144	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5145	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineGL261	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5146	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5147	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5148	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5149	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5150	Virus nameSemliki forest virus	Virus strainwild type SFV4	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5151	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.001 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5152	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.01 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5153	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5154	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889
IDOV_5155	Virus nameSemliki forest virus	Virus strainSFVmiRT	Virus genome typeRNA	Virus familyAlphaviridae	Virus genome modificationInsertional mutagenesis at 3UTr for miR124, 125 and 134	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine glioma cell line	Cell lineCT-2A	Concentration of cell line20000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce production of IFN gamma	Clinical trialNA	PMID27637889